17.08
0.51 (3.08%)
| Previous Close | 16.57 |
| Open | 16.57 |
| Volume | 2,507,946 |
| Avg. Volume (3M) | 4,331,738 |
| Market Cap | 1,210,979,840 |
| Price / Earnings (Forward) | 14.71 |
| Price / Book | 8.44 |
| 52 Weeks Range | |
| Earnings Date | 13 Nov 2025 |
| Diluted EPS (TTM) | -3.04 |
| Current Ratio (MRQ) | 1.16 |
| Operating Cash Flow (TTM) | -142.86 M |
| Levered Free Cash Flow (TTM) | -102.50 M |
| Return on Assets (TTM) | -30.70% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Omeros Corporation | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | -4.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | 0.25 |
|
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 4.40% |
| % Held by Institutions | 47.30% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Ingalls & Snyder Llc | 30 Sep 2025 | 4,106,598 |
| Bank Of Montreal /Can/ | 30 Sep 2025 | 563,095 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 45.00 (WBB Securities, 163.47%) | Buy |
| Median | 36.00 (110.77%) | |
| Low | 20.00 (HC Wainwright & Co., 17.10%) | Buy |
| Average | 33.67 (97.13%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 12.07 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| D. Boral Capital | 24 Dec 2025 | 36.00 (110.77%) | Buy | 15.36 |
| 01 Dec 2025 | 36.00 (110.77%) | Buy | 9.68 | |
| HC Wainwright & Co. | 15 Oct 2025 | 20.00 (17.10%) | Buy | 10.42 |
| WBB Securities | 15 Oct 2025 | 45.00 (163.47%) | Buy | 10.42 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 26 Dec 2025 | Announcement | Omeros Announces New Date for YARTEMLEA® Approval Conference Call |
| 24 Dec 2025 | Announcement | FDA Approves Omeros’ YARTEMLEA® – First and Only Therapy Indicated for TA-TMA |
| 01 Dec 2025 | Announcement | Omeros Corporation Announces Closing of Asset Purchase and License Agreement with Novo Nordisk for Omeros’ Clinical-Stage MASP-3 Inhibitor Zaltenibart (OMS906) |
| 13 Nov 2025 | Announcement | Omeros Corporation Reports Third Quarter 2025 Financial Results |
| 11 Nov 2025 | Announcement | Omeros Corporation to Announce Third Quarter Financial Results on November 13, 2025 |
| 16 Oct 2025 | Announcement | Omeros Announces Publication Highlighting Survival Benefits in TA-TMA Patients Treated with Narsoplimab Versus a Well-Matched External Control Group |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |